Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.

ABSTRACT:

Purpose

Response to adjuvant chemotherapy after tumor resection varies widely among patients with non-small cell lung cancer (NSCLC); therefore, it is of clinical importance to prospectively predict who will benefit from adjuvant chemotherapy before starting the treatment. The goal of this study is to validate a 12-gene adjuvant chemotherapy predictive signature developed from a previous study using a clinical-grade assay.

Experimental design

We developed a clinical-grade assay for formalin-fixed, paraffin-embedded (FFPE) samples using the NanoString nCounter platform to measure the mRNA expression of the previously published 12-gene set. The predictive performance was validated in a cohort of 207 patients with early-stage resected NSCLC with matched propensity score of adju

SUBMITTER: Xie Y 

PROVIDER: S-EPMC7274213 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature